Table 1 Trial Characteristics (N = 166)
From: Use and misuse of common terminology criteria for adverse events in cancer clinical trials
Characteristic | No. | % |
|---|---|---|
Sample size | ||
Median | 836 | |
Range | 154-4,984 | |
Placebo controlled | 68 | 41 |
Intervention type | ||
Chemotherapy | 42 | 25 |
Targeted therapy | 61 | 37 |
Chemotherapy plus targeted therapy | 63 | 38 |
Trial met the primary end point | 71 | 43 |
Funding source | ||
Industry | 111 | 67 |
Government | 10 | 6 |
Industry and government | 33 | 20 |
Not reported | 12 | 7 |
Cancer type | ||
Breast | 38 | 23 |
Colorectal | 17 | 10 |
Lung | 41 | 25 |
Gastric or Gastroesophageal | 10 | 6 |
Other | 59 | 35 |
Journal | ||
Annals of Oncology | 12 | 7 |
The New England Journal of Medicine | 10 | 6 |
Journal of Clinical Oncology | 76 | 45 |
Lancet Oncology | 50 | 30 |
Other | 18 | 11 |
Year of publication | ||
2011 | 49 | 30 |
2012 | 53 | 32 |
2013 | 64 | 38 |
Impact factor of journals | ||
Median | 19.6 | |
Range | 3-53 | |
Cancer stage | ||
Adjuvant and/or neoadjuvant | 25 | 15 |
Metastatic | 141 | 85 |